ArticleAmerican journal of public health2009
What should an ideal vaccine postlicensure safety system be?
Article in American journal of public health, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Post-Marketing Active Surveillance of Adverse Events Following Quadrivalent Subunit Influenza Vaccine in Healthy Participants Aged ≥ 3 Years in China.Infectious diseases and therapy · 2026Article
- Post-marketing safety profile of meningococcal group B vaccines: a real-world disproportionality analysis of the VAERS database, 2015Q1-2025Q3.Frontiers in pharmacology · 2026Article
- Article
- Vaccine Adverse Event Mining of Twitter Conversations: 2-Phase Classification Study.JMIR medical informatics · 2022Article
- Article
- Article
- Use of routinely collected electronic healthcare data for postlicensure vaccine safety signal detection: a systematic review.BMJ global health · 2019Article
- Article
- Consumer reporting of adverse events following immunization (AEFI): identifying predictors of reporting an AEFI.Human vaccines & immunotherapeutics · 2014Article
- Healthcare providers' knowledge, experience and challenges of reporting adverse events following immunisation: a qualitative study.BMC health services research · 2013Article
- The first rotavirus vaccine and the politics of acceptable risk.The Milbank quarterly · 2012Review
- Interleukin-1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus.Journal of virology · 2010Article
- Cardiovascular complications of COVID-19 vaccines: A review of case-report and case-series studies.Heart & lung : the journal of critical careReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2007 the National Vaccine Program, along with the Centers for Disease Control and Prevention, the Food and Drug Administration, the National Institutes of Health, and the Health Resources and Services Administration, sponsored a public conference titled "Vaccine Safety Evaluation: Post Marketing Surveillance." The objective was to discuss enhanced approaches to postlicensure evaluation of vaccine safety, including active and passive surveillance systems and special studies. The conference participants reviewed the evolution of the assessment of vaccine safety, detailed current national approaches to postmarketing safety, and offered new approaches to evaluating vaccine safety. A number of the participants recommended that information systems be expanded to include reliable information on vaccination and health outcomes in large populations. We summarize the major meeting presentations and discussions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.